February 19, 2025
Treatment Resistant Depression Market

Treatment Resistant Depression Market Driven By Increasing Research Funding

Treatment resistant depression refers to depression that does not improve after several trials of different antidepressant medications, often taken sequentially in adequate doses for adequate durations. Some of the common antidepressant medications prescribed for major depressive disorder include selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), bupropion, mirtazapine and tricyclic antidepressants. Around 30% of patients do not respond to at least two antidepressant medications. Treatment resistant depression poses a substantial challenge to mental healthcare professionals globally. The use of augmentation strategies, combination therapies, and novel treatment options are being explored actively to improve clinical outcomes in such patients.

The global Treatment Resistant Depression Market is estimated to be valued at US$ 1220.12 Mn in 2023 and is expected to exhibit a CAGR of 3.4% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market key trends:
One of the key trends in the global treatment resistant depression market is the increasing research funding for novel treatment approaches. Major depression is a serious, chronic and debilitating illness affecting millions of individuals worldwide. Despite significant progress, many patients do not achieve full remission even after multiple antidepressant trials. This has led funding agencies like the National Institute of Mental Health to allocate sizeable funding towards research on novel therapeutics, predictive biomarkers and neuroimaging methods that may help overcome treatment resistance. Several pharma/biotech companies are also actively conducting clinical trials evaluating potential new drug targets like glutamate modulators, neuropeptides and ketamine metabolites for difficult-to-treat depression. It is expected that large scale research initiatives and private sector drug development programs will expand the treatment options available for managing treatment resistant depression over the coming years.

Porter’s Analysis

Threat of new entrants: Low barriers for generics companies to enter the market make threat of new entrants moderate. Bargaining power of buyers: Large pharmacy benefit managers and hospitals have significant bargaining power over manufacturers. Bargaining power of suppliers: Few suppliers dominate API and key starting material markets giving them moderate bargaining power. Threat of new substitutes: Substitutes from other therapeutic areas pose low threat currently. Competitive rivalry: Strong competition from large generic players and biosimilars increases competitive rivalry in the market.

Key Takeaways

Global Treatment Resistant Depression Market Demand is expected to witness high growth. Regional analysis comprises North America dominates the global Treatment Resistant Depression market currently owing to rising prevalence of depression and favorable reimbursement policies. Europe is the second largest market driven by high treatment rates. Asia Pacific is expected to be the fastest growing market over the forecast period with increasing awareness.

Key players operating in the Treatment Resistant Depression market are AbbVie Inc., Lupin, Eli Lilly and Company, GlaxoSmithKline Plc., Pfizer Inc., Bausch Health Companies Inc., Sanofi, Mallinckrodt, Johnson & Johnson, Merck & Co., Inc., Viatris Inc., Otsuka Holdings Co., Ltd., H. Lundbeck A/S, AstraZeneca, and Aurobindo Pharma Ltd.

Regional analysis related content comprises North America dominates the global Treatment Resistant Depression market currently owing to rising prevalence of depression and favorable reimbursement policies. Europe is the second largest market driven by high treatment rates. Asia Pacific is expected to be the fastest growing market over the forecast period with increasing awareness.

*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it

Money Singh
+ posts

Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemicals and materials, defense and aerospace, consumer goods, etc. 

Money Singh

Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemicals and materials, defense and aerospace, consumer goods, etc. 

View all posts by Money Singh →